tiprankstipranks
Trending News
More News >
Lucid Diagnostics (LUCD)
NASDAQ:LUCD
US Market

Lucid Diagnostics (LUCD) Stock Forecast & Price Target

Compare
475 Followers
See the Price Targets and Ratings of:

LUCD Analyst Ratings

Strong Buy
6Ratings
Strong Buy
6 Buy
0 Hold
0 Sell
Based on 6 analysts giving stock ratings to
Lucid
Diagnostics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

LUCD Stock 12 Month Forecast

Average Price Target

$3.79
▲(193.80%Upside)
Based on 6 Wall Street analysts offering 12 month price targets for Lucid Diagnostics in the last 3 months. The average price target is $3.79 with a high forecast of $7.75 and a low forecast of $2.00. The average price target represents a 193.80% change from the last price of $1.29.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","-1":"-$1","1.25":"$1.25","3.5":"$3.5","5.75":"$5.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.79,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$3.79</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.25,3.5,5.75,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2024","6":"Aug<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.24,1.7407692307692306,2.2415384615384615,2.7423076923076923,3.2430769230769227,3.743846153846154,4.2446153846153845,4.745384615384615,5.246153846153846,5.746923076923077,6.247692307692308,6.748461538461538,7.249230769230769,{"y":7.75,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.24,1.4361538461538461,1.6323076923076922,1.8284615384615384,2.0246153846153847,2.2207692307692306,2.416923076923077,2.613076923076923,2.809230769230769,3.0053846153846155,3.2015384615384614,3.3976923076923073,3.5938461538461537,{"y":3.79,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.24,1.2984615384615386,1.356923076923077,1.4153846153846155,1.4738461538461538,1.5323076923076924,1.5907692307692307,1.6492307692307693,1.7076923076923076,1.7661538461538462,1.8246153846153845,1.883076923076923,1.9415384615384617,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.4,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.44,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.24,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.9,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.88,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.89,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.8,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.82,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.92,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.48,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.42,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.29,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.24,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$7.75Average Price Target$3.79Lowest Price Target$2.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on LUCD
TipRanks AITipRanks
Not Ranked
TipRanks
$1.5
Hold
16.28%
Upside
Reiterated
06/07/25
Lucid Diagnostics' score is driven by its strong revenue growth and strategic advancements highlighted in the earnings call. However, substantial financial instability due to negative profitability, cash flow challenges, and valuation concerns weigh on the overall score.
Ascendiant Analyst forecast on LUCD
Edward WooAscendiant
Ascendiant
$7.5$7.75
Buy
500.78%
Upside
Reiterated
06/06/25
Lucid Diagnostics price target raised to $7.75 from $7.50 at AscendiantLucid Diagnostics price target raised to $7.75 from $7.50 at Ascendiant
Cantor Fitzgerald Analyst forecast on LUCD
Ross OsbornCantor Fitzgerald
Cantor Fitzgerald
$2
Buy
55.04%
Upside
Reiterated
05/19/25
Cantor Fitzgerald reiterates Overweight Rating on Lucid Diagnostics Inc (LUCD)Cantor Fitzgerald analyst Ross Osborn reiterated an Overweight rating and $2.00 price target on Lucid Diagnostics Inc (NASDAQ: LUCD).
Canaccord Genuity Analyst forecast on LUCD
Kyle Mikson CFACanaccord Genuity
Canaccord Genuity
$3
Buy
132.56%
Upside
Reiterated
05/15/25
Anticipated Medicare Coverage and Strategic Positioning Drive Buy Rating for Lucid Diagnostics
BTIG
$2
Buy
55.04%
Upside
Reiterated
05/15/25
Analysts Offer Insights on Healthcare Companies: Nuvation Bio (NYSE: NUVB), Lucid Diagnostics (NASDAQ: LUCD) and Arcellx Inc (NASDAQ: ACLX)
Maxim Group Analyst forecast on LUCD
Anthony VendettiMaxim Group
Maxim Group
$5
Buy
287.60%
Upside
Reiterated
05/15/25
Analysts' Top Healthcare Picks: Astrana Health (ASTH), NexGel Inc (NXGL)
Needham
$3
Buy
132.56%
Upside
Reiterated
05/14/25
Lucid Diagnostics: Strong Cash Position and Growing EsoGuard Test Volumes Justify Buy Rating
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on LUCD
TipRanks AITipRanks
Not Ranked
TipRanks
$1.5
Hold
16.28%
Upside
Reiterated
06/07/25
Lucid Diagnostics' score is driven by its strong revenue growth and strategic advancements highlighted in the earnings call. However, substantial financial instability due to negative profitability, cash flow challenges, and valuation concerns weigh on the overall score.
Ascendiant Analyst forecast on LUCD
Edward WooAscendiant
Ascendiant
$7.5$7.75
Buy
500.78%
Upside
Reiterated
06/06/25
Lucid Diagnostics price target raised to $7.75 from $7.50 at AscendiantLucid Diagnostics price target raised to $7.75 from $7.50 at Ascendiant
Cantor Fitzgerald Analyst forecast on LUCD
Ross OsbornCantor Fitzgerald
Cantor Fitzgerald
$2
Buy
55.04%
Upside
Reiterated
05/19/25
Cantor Fitzgerald reiterates Overweight Rating on Lucid Diagnostics Inc (LUCD)Cantor Fitzgerald analyst Ross Osborn reiterated an Overweight rating and $2.00 price target on Lucid Diagnostics Inc (NASDAQ: LUCD).
Canaccord Genuity Analyst forecast on LUCD
Kyle Mikson CFACanaccord Genuity
Canaccord Genuity
$3
Buy
132.56%
Upside
Reiterated
05/15/25
Anticipated Medicare Coverage and Strategic Positioning Drive Buy Rating for Lucid Diagnostics
BTIG
$2
Buy
55.04%
Upside
Reiterated
05/15/25
Analysts Offer Insights on Healthcare Companies: Nuvation Bio (NYSE: NUVB), Lucid Diagnostics (NASDAQ: LUCD) and Arcellx Inc (NASDAQ: ACLX)
Maxim Group Analyst forecast on LUCD
Anthony VendettiMaxim Group
Maxim Group
$5
Buy
287.60%
Upside
Reiterated
05/15/25
Analysts' Top Healthcare Picks: Astrana Health (ASTH), NexGel Inc (NXGL)
Needham
$3
Buy
132.56%
Upside
Reiterated
05/14/25
Lucid Diagnostics: Strong Cash Position and Growing EsoGuard Test Volumes Justify Buy Rating
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Lucid Diagnostics

1 Month
xxx
Success Rate
7/15 ratings generated profit
47%
Average Return
-8.31%
reiterated a xxx
rating 27 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 46.67% of your transactions generating a profit, with an average return of -8.31% per trade.
3 Months
xxx
Success Rate
5/15 ratings generated profit
33%
Average Return
-5.34%
reiterated a xxx
rating 27 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 33.33% of your transactions generating a profit, with an average return of -5.34% per trade.
1 Year
Success Rate
8/21 ratings generated profit
38%
Average Return
-17.75%
reiterated a buy rating 28 days ago
Copying Michael Matson's trades and holding each position for 1 Year would result in 38.10% of your transactions generating a profit, with an average return of -17.75% per trade.
2 Years
xxx
Success Rate
5/15 ratings generated profit
33%
Average Return
-16.99%
reiterated a xxx
rating 27 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 33.33% of your transactions generating a profit, with an average return of -16.99% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

LUCD Analyst Recommendation Trends

Rating
Nov 24
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
10
12
12
13
8
Buy
0
3
3
3
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
10
15
15
16
8
In the current month, LUCD has received 8 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. LUCD average Analyst price target in the past 3 months is 3.79.
Each month's total comprises the sum of three months' worth of ratings.

LUCD Financial Forecast

LUCD Earnings Forecast

Next quarter’s earnings estimate for LUCD is -$0.11 with a range of -$0.15 to -$0.08. The previous quarter’s EPS was -$0.16. LUCD beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.03% of the time in the same period. In the last calendar year LUCD has Outperformed its overall industry.
Next quarter’s earnings estimate for LUCD is -$0.11 with a range of -$0.15 to -$0.08. The previous quarter’s EPS was -$0.16. LUCD beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.03% of the time in the same period. In the last calendar year LUCD has Outperformed its overall industry.

LUCD Sales Forecast

Next quarter’s sales forecast for LUCD is $1.24M with a range of $1.00M to $1.50M. The previous quarter’s sales results were $828.00K. LUCD beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.45% of the time in the same period. In the last calendar year LUCD has Outperformed its overall industry.
Next quarter’s sales forecast for LUCD is $1.24M with a range of $1.00M to $1.50M. The previous quarter’s sales results were $828.00K. LUCD beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.45% of the time in the same period. In the last calendar year LUCD has Outperformed its overall industry.

LUCD Stock Forecast FAQ

What is LUCD’s average 12-month price target, according to analysts?
Based on analyst ratings, Lucid Diagnostics’s 12-month average price target is 3.79.
    What is LUCD’s upside potential, based on the analysts’ average price target?
    Lucid Diagnostics has 193.80% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is LUCD a Buy, Sell or Hold?
          Lucid Diagnostics has a consensus rating of Strong Buy which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Lucid Diagnostics’s price target?
            The average price target for Lucid Diagnostics is 3.79. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $7.75 ,the lowest forecast is $2.00. The average price target represents 193.80% Increase from the current price of $1.29.
              What do analysts say about Lucid Diagnostics?
              Lucid Diagnostics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
                How can I buy shares of LUCD?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis